This article is more than 5 years old. Information may no longer be current.

Tecentriq, Avastin combination improves survival in unresectable HCC

Combination treatment with Tecentriq and Avastin for unresectable hepatocellular carcinoma in patients without prior systemic therapy demonstrated clinically meaningful improvements in both overall and progression-free survival compared with Nexavar, according to a press release from Genentech.

“We are very pleased with the results of our study testing the combination of Tecentriq and Avastin, which marks the first treatment in more than a decade to improve overall survival in people with unresectable hepatocellular carcinoma who have not received prior systemic therapy,” Levi Garraway, MD, PhD, chief medical officer and head of global product development at Genentech, said in the release. “HCC is a major cause of death globally and particularly in Asia, making this study an important step in our mission of addressing unmet medical needs for patients around the world.”

The phase 3 IMbrave150 study comprised 501 patients with unresectable HCC without prior systemic therapy who received either treatment with Tecentriq (atezolizumab) and Avastin (bevacizumab) or treatment with Nexavar (sorafenib, Bayer).

Patients in all groups received treatment until investigators determined unacceptable toxicity or loss of clinical benefit. The combination therapy met both of its primary endpoints, overall survival and progression-free survival, and demonstrated a safety profile consistent with previous studies of atezolizumab and bevacizumab.

“We will submit these data to global health authorities as soon as possible,” Garraway said. “Our hope is to bring a new treatment to people with this aggressive disease who currently have limited options.”

Reference: www.gene.com